Image
Photograph of a female healthcare provider in a clinic setting, speaking with an older woman patient
Image
Photograph of a female healthcare provider in a clinic setting, speaking with an older woman patient
Image
Photograph of a female healthcare provider in a clinic setting, speaking with an older woman patient

Information for patients and healthcare providers

Visit these websites to learn more about our approved product, and for information about our educational and financial support programs for qualified patients.

View full Prescribing Information and Medication Guide

Open PDF

Urovant offers resources for information, advocacy, and support.

Learn more

Safety and reporting adverse events

At Urovant Sciences, we are committed to high standards of product safety, efficacy, and regulatory compliance, including adherence to post-market requirements for reporting adverse events, product complaints, and other reportable events.

Urovant Sciences’ Pharmacovigilance and Product Complaint policy establishes that all employees and agents are part of the Pharmacovigilance System (PV System) and that the PV System performance depends on all stakeholders being aware of and contributing to its activities.

Pharmacovigilance is a companywide, global concept, spanning the whole lifecycle of a product. Although some functions will be more involved than others, every individual in the organization is required to learn about and understand pharmacovigilance-relevant information relating to the products for which the company holds a marketing authorization.

+1 833 876 8268

For medical inquiries: medinfo@urovant.com

Patent notices

Please see the following list for US patents covering Urovant Sciences’ products. The absence of a product name from this list, or the absence of a US patent number as associated with any listed product, does not constitute a waiver of Urovant Sciences’ patent rights, or any other intellectual property rights, concerning that product.

GEMTESA® (vibegron)

US 8,247,415

US 8,653,260

US 9,809,536

US 9,822,121

US 10,087,189

US 10,287,289

US 10,435,410

US 10,577,316

US 10,696,681

US 8,247,415

US 8,653,260

US 9,809,536

US 9,822,121

US 10,087,189

US 10,287,289

US 10,435,410

US 10,577,316

US 10,696,681